Arcus Biosciences RCUS
NYSE RCUS
$29.69 -0.44 (-1.46%)
As of: Sep 4, 2026 · 1:34 PM EDT

Arcus Biosciences (RCUS) EV to CFO (2018 - 2026)

Analysis

Arcus Biosciences (RCUS) EV to CFO (2018 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 139.27 Bn 131.42 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.55 Bn 77.56 Bn 3.93 Bn
3 Argenx Se 63.45 Bn 58.27 Bn 1.37 Bn
4 Moderna 57.73 Bn 52.59 Bn 52.00 Mn
5 Revolution Medicines 44.08 Bn 44.08 Bn -
6 BeOne Medicines 39.95 Bn 34.85 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.14 Bn 31.84 Bn 992.69 Mn
8 Royalty Pharma 28.44 Bn 27.60 Bn -
9 Insmed 27.32 Bn 26.16 Bn 358.27 Mn
10 Arcus Biosciences 3.74 Bn 3.04 Bn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -27.00
Mar 31, 2026 -13.69
Dec 31, 2025 -16.71
Sep 30, 2025 -6.45
Jun 30, 2025 0.34
Mar 31, 2025 1.26
Dec 31, 2024 -3.95
Sep 30, 2024 11.92
Jun 30, 2024 -4.48
Mar 31, 2024 -360.60
Dec 31, 2023 -7.76
Sep 30, 2023 -8.63
Jun 30, 2023 -10.23
Mar 31, 2023 -3.87
Dec 31, 2022 -7.12
Sep 30, 2022 -10.41
Jun 30, 2022 -10.05
Mar 31, 2022 1.60
Dec 31, 2021 -38.20
Sep 30, 2021 -35.80